[
  {
    "ts": "2026-02-13T01:14:37+00:00",
    "headline": "Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update",
    "summary": "Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its inflammation and immunology portfolio, discussing expansion plans for UPLIZNA, new phase II results for daxdilimab in discoid lupus, progress in Sjögren’s syndrome studies for dazodalib",
    "url": "https://www.marketbeat.com/instant-alerts/amgen-conference-uplizna-phase-iii-plans-daxdilimab-lupus-data-and-tezspire-expansion-update-2026-02-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "f9fd3d54-bf00-3c0e-a799-8b830c93380f",
      "content": {
        "id": "f9fd3d54-bf00-3c0e-a799-8b830c93380f",
        "contentType": "STORY",
        "title": "Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update",
        "description": "",
        "summary": "Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its inflammation and immunology portfolio, discussing expansion plans for UPLIZNA, new phase II results for daxdilimab in discoid lupus, progress in Sjögren’s syndrome studies for dazodalib",
        "pubDate": "2026-02-13T01:14:37Z",
        "displayTime": "2026-02-13T01:14:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/4909f551de818c56e42d3c9ab5f5456b",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Amgen logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/du5DeAl0vfsu8qD9DGoJyw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/4909f551de818c56e42d3c9ab5f5456b.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GeOU9jSAhtvzM5tx5QWlcw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/4909f551de818c56e42d3c9ab5f5456b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/amgen-conference-uplizna-phase-iii-plans-daxdilimab-lupus-data-and-tezspire-expansion-update-2026-02-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-conference-uplizna-phase-iii-011437083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:43+00:00",
    "headline": "Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best medical research stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) received rating updates from Argus Research and Guggenheim on February 6. Argus reiterated a Buy rating on the stock with a $400 price target, while Guggenheim reaffirmed a Hold rating on Amgen Inc. (NASDAQ:AMGN) and […]",
    "url": "https://finance.yahoo.com/news/argus-research-guggenheim-saying-amgen-145743634.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "9143839c-c5cc-3a32-bb16-9a20c3a31205",
      "content": {
        "id": "9143839c-c5cc-3a32-bb16-9a20c3a31205",
        "contentType": "STORY",
        "title": "Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)",
        "description": "",
        "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best medical research stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) received rating updates from Argus Research and Guggenheim on February 6. Argus reiterated a Buy rating on the stock with a $400 price target, while Guggenheim reaffirmed a Hold rating on Amgen Inc. (NASDAQ:AMGN) and […]",
        "pubDate": "2026-02-13T14:57:43Z",
        "displayTime": "2026-02-13T14:57:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "RBC Lifts Amgen (AMGN) Target After Strong Q4, Cites Key Drug Momentum",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fl9k_iPg0JyfVI.qZJRd8A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RgojEqpZ8ITlaPGpQimL8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/argus-research-guggenheim-saying-amgen-145743634.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/argus-research-guggenheim-saying-amgen-145743634.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]